在牙科中应用i-PRF
Wojciech Niemczyk1, Stanisław Niemczyk2, Olga Odrzywolska1
1FACULTY OF MEDICAL SCIENCES IN ZABRZE, MEDICAL UNIVERSITY OF SILESIA, ZABRZE, POLAND.
概括
可注射的富血小板纤维素 (i-PRF) 在牙科中促进组织再生. 这种无抗凝固剂的缩剂在牙周科,口腔外科和正牙科中提供了增强的治疗效果.
科学领域:
- 生物材料科学 生物材料科学
- 再生医学是一种再生医学.
- 牙科应用 牙科应用
背景情况:
- 可注射的富血小板纤维素 (i-PRF) 是一种用于组织再生的新型血小板缩物.
- 与富血小板血 (PRP) 不同,i-PRF无抗凝剂,具有成本效益,易于处理.
- 2014年开发的i-PRF在10-14天内转化为富含生长因子的凝块.
研究的目的:
- 审查i-PRF在各种牙科应用中的有效性.
- 突出i-PRF在促进组织再生和愈合方面的潜力.
- 将i-PRF与其他再生疗法进行比较.
主要方法:
- 审查关于i-PRF在牙科应用的现有文献.
- 对i-PRF的特性和程序方面的分析.
- 在牙周科,口腔外科,正牙科和内牙科中评估临床结果.
主要成果:
- i-PRF有效治疗牙周炎,增强牙的厚度和减少炎症.
- 它在口腔外科手术中促进骨再生,在正牙科中加速牙运动.
- 有限的研究表明,i-PRF支持牙周内科的重血管化和周围牙愈合.
结论:
- 在牙科中,i-PRF具有显著的再生,抗炎和抗菌潜力.
- 它的易用性和成本效益使其成为一个有前途的治疗剂.
- 需要进一步的研究和i-PRF的临床应用.
相关概念视频
Formation of the Platelet Plug
4.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
4.2K
Clot Retraction and Fibrinolysis
3.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.8K
Introduction to Hemostasis
5.5K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
5.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
467
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
467
Anticoagulant Drugs: Low-Molecular-Weight Heparins
608
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
608


